The Truth About Thyroid Concerns with GLP-1s

Where the Concern Started

Early rodent studies showed C-cell thyroid tumors in rats given extremely high doses of GLP-1 drugs.

That led to the FDA’s required warning label—but humans and rodents have very different C-cell receptor densities.

To date, no increase in medullary thyroid carcinoma (MTC) has been demonstrated in human trials.

What the Human Data Show

Across large studies (STEP 1–5, SURMOUNT 1–2, SUSTAIN 1–10), zero confirmed MTC cases were reported.
GLP-1 receptors in human thyroid tissue are scarce.
The medications have not been shown to raise TSH or cause hypothyroidism in euthyroid patients.

The warning remains purely precautionary, especially for people with a personal or family history of MTC or MEN-2.

At our GLP-1 telehealth clinic, every patient is screened for personal or family thyroid history before any GLP-1 is prescribed — we also offer a retatrutide online prescription as an alternative for patients where semaglutide or tirzepatide may not be appropriate.

If You Have Thyroid Disease

Most thyroid disorders—Hashimoto’s, hypothyroidism, or simple nodules—are not contraindications.

If your thyroid levels are stable, GLP-1s are considered safe.
Monitoring TSH every 6–12 months is standard practice.

The Bottom Line

GLP-1s are among the most well-studied metabolic medications in history.
For the general population, the benefits far outweigh the theoretical thyroid risk.

If you have a strong family history of thyroid cancer or MEN-2, discuss alternative therapies—but for everyone else, GLP-1s remain a safe and powerful option.

Start Confidently

Join a medically supervised GLP-1 program with Dr Sara and get clear, evidence-based guidance on your thyroid and metabolism. Learn more at drbrainrx.com.